Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Ascendis Pharma is applying its innovative TransConTM technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives.
Guided by our core values of patients, science and passion, we utilize our technology platform to create new and potentially best-in-class therapies. We currently have a pipeline of three independent, rare disease endocrinology product candidates in clinical development. We have also established oncology as our second therapeutic area of focus.
Biomedica provides internationally recognized, high quality ELISAs which are fully validated for clinical research. For specific markers Biomedica has become a world-wide market leader, e.g. Slerostin, DKK-1, free sRANKL and OPG, with a continuously growing portfolio.
Most assays are CE marked and ready-for-use in IVD. Biomedica uses serum-based calibrators and controls enabling researchers to collect biologically reliable data.
This year’s highlights: FGF23 ELISAs (intact, C-terminal), VEGF ELISA, FluoBolt Klotho FIA
Partner and products: TAmiRNA’s osteomiR™ kit, Fianostics’ FluoBolt™ FIAs..
Service measurements are available on request.
Visit us at Biomedica’s booth #6 for details.
Bruker-MicroCT develops and manufactures micro and nano-CT scanners both in vivo and ex vivo, with the highest resolution and imaging performance over both categories. Bruker SkyScan scanners have been essential tools for bone researchers for more than 2 decades. In-vivo imaging with physiological monitoring is within proven safe dose limits. Scanners are supplied with comprehensive analysis software featuring high speed GPU reconstruction, versatile volume of interest selection tools including trabecular-cortical separation, calibrated BMD/TMD, comprehensive 3d and 2d parameters (ASBMR-compliant) and customisable batch operations. In-depth bone research and morphometry support is provided. Bruker-MicroCT customers are closely supported by 66 distributors worldwide.
European Calcified Tissue Society
The European Calcified Tissue Society is a medical society bringing together researchers and clinicians working in the field of calcified tissues and related fields. For over 50 years, ECTS is dedicated to pursuing excellence in research, best practices and in providing education to all those interested in the field. While ECTS is founded in Europe, we engage globally with all stakeholders in the field.
Membership is open to anyone working in the field at whatever stage in their career. Come and meet us in Marseille at our booth.
Visit our website www.ectsoc.org and follow up on twitter @ECTS_soc | @ECTS_science
Fresenius Kabi France
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.
Our products and services are used to help care for critically and chronically ill patients. Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products.
In the field of nephrology, Fresenius Kabi offers specific products to better control the kidney function of patients with chronic kidney disease.
Gedeon Richter Plc., Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, China and Latin America. Richter’s consolidated sales were approximately EUR 1.56 billion in 2019, reaching a market capitalisation of EUR 4.1 billion. Richter’s product portfolio covers many important therapeutic areas, including Women’s Healthcare and Central Nervous System. Richter is also active in biologic product development, and committed to bringing biosimilar products to global markets.
International Conference on Children’s Bone Health (ICCBH)
3-6 July 2021, Dublin, Ireland | Abstract deadline: 15 February 2021
ICCBH is your opportunity to hear about and discuss the newest developments in our understanding of paediatric bone health and disease.
We invite anyone with an interest in bone metabolism and bone mass in children, adolescents and young adults to attend. The biennial ICCBH conference is attended by over 600 delegates from across the globe, making it truly multinational and multidisciplinary – a unique networking opportunity.
In addition for 2021, ICCBH Bone School takes place in Dublin 30 June to 2 July – a 3-day educational course on paediatric bone health and rare bone diseases.
Come and participate in a lively interactive meeting with the leaders in the field!
Kyowa Kirin commits to innovative drug discovery driven by state-of-the-art technologies. The company focuses on creating new values in the four therapeutic areas: nephrology, oncology, immunology/allergy and neurology. Under the Kyowa Kirin brand, the employees from 36 group companies across North America, EMEA and Asia/Oceania unite to champion the interests of patients and their caregivers in discovering solutions wherever there are unmet medical needs.
Nestle Nutrition a division of Nestlé Enterprise S.A
The Nestlé Nutrition Institute (NNI), as a non for profit association in Switzerland, shares leading science based information and education with practicing health professionals in all parts of the world. NNI is committed to foster the highest levels of discussion within scientific community and build nutrition knowledge globally. All NNI exclusive resources are available at http://www.nestlenutrition-institute.org.
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.
UCB Biopharma SRL
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives Follow us on Twitter:@UCB_news.